tetano
Editor, Senior Moderator
Front Immunol
. 2020 Aug 26;11:2037.
doi: 10.3389/fimmu.2020.02037. eCollection 2020.
The Immune Response and Immunopathology of COVID-19
Esmaeil Mortaz[SUP] 1 2 [/SUP], Payam Tabarsi[SUP] 1 [/SUP], Mohammad Varahram[SUP] 3 [/SUP], Gert Folkerts[SUP] 4 [/SUP], Ian M Adcock[SUP] 5 6 [/SUP]
Affiliations
Abstract
Coronaviruses were first discovered in the 1960s and are named due to their crown-like shape. Sometimes, but not often, a coronavirus can infect both animals and humans. An acute respiratory disease, caused by a novel coronavirus (severe acute respiratory syndrome coronavirus-2 or SARS-CoV-2 previously known as 2019-nCoV) was identified as the cause of coronavirus disease 2019 (COVID-19) as it spread throughout China and subsequently across the globe. As of 14th July 2020, a total of 13.1 million confirmed cases globally and 572,426 deaths had been reported by the World Health Organization (WHO). SARS-CoV-2 belongs to the β-coronavirus family and shares extensive genomic identity with bat coronavirus suggesting that bats are the natural host. SARS-CoV-2 uses the same receptor, angiotensin-converting enzyme 2 (ACE2), as that for SARS-CoV, the coronavirus associated with the SARS outbreak in 2003. It mainly spreads through the respiratory tract with lymphopenia and cytokine storms occuring in the blood of subjects with severe disease. This suggests the existence of immunological dysregulation as an accompanying event during severe illness caused by this virus. The early recognition of this immunological phenotype could assist prompt recognition of patients who will progress to severe disease. Here we review the data of the immune response during COVID-19 infection. The current review summarizes our understanding of how immune dysregulation and altered cytokine networks contribute to the pathophysiology of COVID-19 patients.
Keywords: IL-6; SARS-CoV; SARS-CoV-2; coronavirus; cytokines storm; pathogenesis.
. 2020 Aug 26;11:2037.
doi: 10.3389/fimmu.2020.02037. eCollection 2020.
The Immune Response and Immunopathology of COVID-19
Esmaeil Mortaz[SUP] 1 2 [/SUP], Payam Tabarsi[SUP] 1 [/SUP], Mohammad Varahram[SUP] 3 [/SUP], Gert Folkerts[SUP] 4 [/SUP], Ian M Adcock[SUP] 5 6 [/SUP]
Affiliations
- PMID: 32983152
- PMCID: PMC7479965
- DOI: 10.3389/fimmu.2020.02037
Abstract
Coronaviruses were first discovered in the 1960s and are named due to their crown-like shape. Sometimes, but not often, a coronavirus can infect both animals and humans. An acute respiratory disease, caused by a novel coronavirus (severe acute respiratory syndrome coronavirus-2 or SARS-CoV-2 previously known as 2019-nCoV) was identified as the cause of coronavirus disease 2019 (COVID-19) as it spread throughout China and subsequently across the globe. As of 14th July 2020, a total of 13.1 million confirmed cases globally and 572,426 deaths had been reported by the World Health Organization (WHO). SARS-CoV-2 belongs to the β-coronavirus family and shares extensive genomic identity with bat coronavirus suggesting that bats are the natural host. SARS-CoV-2 uses the same receptor, angiotensin-converting enzyme 2 (ACE2), as that for SARS-CoV, the coronavirus associated with the SARS outbreak in 2003. It mainly spreads through the respiratory tract with lymphopenia and cytokine storms occuring in the blood of subjects with severe disease. This suggests the existence of immunological dysregulation as an accompanying event during severe illness caused by this virus. The early recognition of this immunological phenotype could assist prompt recognition of patients who will progress to severe disease. Here we review the data of the immune response during COVID-19 infection. The current review summarizes our understanding of how immune dysregulation and altered cytokine networks contribute to the pathophysiology of COVID-19 patients.
Keywords: IL-6; SARS-CoV; SARS-CoV-2; coronavirus; cytokines storm; pathogenesis.